Investigating the role of ARID1a in pulmonary arterial hypertension
The Chromatin Remodeling Factor ARID1a and the Epigenetic Landscape In Pulmonary Arterial Hypertension
This study is looking at how a specific protein called ARID1a influences the development of pulmonary arterial hypertension (PAH), a serious lung condition, and how it interacts with another protein, EZH2, to help find new ways to treat this disease for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11047747 on NIH RePORTER |
What this research studies
This research focuses on understanding how the chromatin remodeling factor ARID1a affects the development of pulmonary arterial hypertension (PAH), a serious and progressive lung disease. Researchers will explore the relationship between ARID1a and another protein, EZH2, to uncover how changes in gene expression contribute to the vascular remodeling seen in PAH. By studying these molecular interactions, the research aims to shed light on potential new therapeutic targets for this condition. Patients with PAH may benefit from insights gained into the underlying mechanisms of their disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension.
Not a fit: Patients with other forms of pulmonary hypertension or those without a confirmed diagnosis of PAH may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for patients suffering from pulmonary arterial hypertension.
How similar studies have performed: While the role of ARID1a in PAH is not extensively studied, similar research in other conditions has shown promising results in understanding chromatin remodeling and its effects on disease.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Hadri, Lahouaria — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hadri, Lahouaria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.